Psychotic Disorders Clinical Trial
— ANTE-UPOfficial title:
A Better Understanding of the Association Between Problem Gambling and Psychotic Disorders in Young Adults: a New Path Towards Recovery
The aim of this observational study is to get a better understanding of the association between problem gambling psychotic disorders among young adults with firs-episode psychosis. The main questions to be answered are: 1. What are the incidence and risk factors for problem gambling in this population? 2. How effective are the current treatments for problem gambling in adults with first-episode psychosis? To do so, comparisons will be made among the study cohort for various factors: - Use of dopamine partial agonists; - Psychiatric comorbidities; - Socioeconomic status; - Sex; - Gender; - Gambling history. The nature of the treatments for problem gambling offered and received by the subjects, as well as their effectiveness, will also be documented.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | May 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - 18 to 35 years old; - Diagnosis of first-episode psychosis (i.e., DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders, as well as DSM-5 bipolar disorder with psychotic features). Exclusion Criteria: - DSM-5 diagnosis of psychotic disorder due to a medical condition; - Severe intellectual disability. |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal University Hospital Center | Montreal | Quebec |
Canada | Quebec Mental Health University Institute | Quebec |
Lead Sponsor | Collaborator |
---|---|
Laval University | Fonds de recherche du Québec |
Canada,
Bergamini A, Turrina C, Bettini F, Toccagni A, Valsecchi P, Sacchetti E, Vita A. At-risk gambling in patients with severe mental illness: Prevalence and associated features. J Behav Addict. 2018 Jun 1;7(2):348-354. doi: 10.1556/2006.7.2018.47. Epub 2018 Jun 5. — View Citation
Corbeil O, Corbeil S, Dorval M, Carmichael PH, Giroux I, Jacques C, Demers MF, Roy MA. Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program. CNS Drugs. 2021 Apr;35(4):461-468. doi: 10.1007/s40263-021-00801-4. Epub 2021 Mar 13. — View Citation
Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers MF, Roy MA. Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports. J Clin Psychopharmacol. 2020 Mar/Apr;40(2):191-194. doi: 10.1097/JCP.0000000000001177. — View Citation
Desai RA, Potenza MN. A cross-sectional study of problem and pathological gambling in patients with schizophrenia/schizoaffective disorder. J Clin Psychiatry. 2009 Sep;70(9):1250-7. doi: 10.4088/JCP.08m04359. Epub 2009 Jun 16. — View Citation
Haydock M, Cowlishaw S, Harvey C, Castle D. Prevalence and correlates of problem gambling in people with psychotic disorders. Compr Psychiatry. 2015 Apr;58:122-9. doi: 10.1016/j.comppsych.2015.01.003. Epub 2015 Jan 15. — View Citation
Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault AS, Roy MA, Demers MF. Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence. J Clin Psychopharmacol. 2019 Jul/Aug;39(4):393-397. doi: 10.1097/JCP.0000000000001068. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At baseline (i.e., at admission in the clinic) | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 6 months | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 12 months | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 18 months | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 24 months | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 30 months | |
Primary | Gambling disorder | Diagnosis of gambling disorder according to DSM-5 criteria, established by the treating psychiatrist | At 36 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At baseline (i.e., at admission in the clinic) | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 6 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 12 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 18 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 24 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 30 months | |
Secondary | Problem gambling | Problem gambing according to a score of 8 and more on the Problem Gambling Severity Index, as questioned by the clinical case manager | At 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130676 -
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |